In a nutshell This study evaluated whether tumor size affected treatment outcomes for patients with early-stage (ES) Hodgkin lymphoma (HL). This study concluded that the risk of cancer recurrence increased with increasing tumor size. Some background PET scanning during treatment is used to guide therapy for patients with HL. Depending on the scan...
Read MoreIn a nutshell This study reviewed treatment options for older patients newly diagnosed with classical Hodgkin lymphoma (cHL). It found that treatments including brentuximab vedotin (BV: Adcetris) are effective in this age group and that avoiding bleomycin (Blenoxane) prevents lung damage. Some background Around 20% of patients diagnosed with cHL...
Read More
In a nutshell This review summarizes current treatment options of advanced classical Hodgkin lymphoma. It found that PET-scan based treatment minimizes long-term side effects and that both ABVD and eBEACOPP are useful chemotherapy regimens. Some background Classical Hodgkin lymphoma (cHL) is a cancer of white blood cells. If cancerous...
Read More
In a nutshell This study evaluated the safety and effectiveness of brentuximab vedotin (Adcetris) in elderly patients with relapsed or unresponsive Hodgkin lymphoma (HL). This study found that this treatment was effective, although frail patients may be at higher risk for side effects. Some background Most patients with HL respond to front-line...
Read More
In a nutshell This article reviews treatment options for patients with classical Hodgkin's lymphoma (cHL) that came back (relapsed) after chemotherapy. This study found that targeted therapies are becoming more prevalent and that patient outcomes have improved. Some background cHL is a cancer of white blood cells called lymphocytes....
Read More
In a nutshell This study evaluated the long-term outcomes of patients with classical Hodgkin’s lymphoma (cHL) that came back after an autologous stem cell transplant (autoSCT). This study found that advancements in treatment have helped improve survival outcomes for patients. Some background Chemotherapy is usually the first-line...
Read More
In a nutshell This study evaluated the effectiveness of brentuximab vedotin (Adcetris) plus bendamustine (Treanda) for patients with hard to treat classical Hodgkin lymphoma (cHL). This study found that this regimen is an effective salvage therapy for these patients. Some background Standard first-line chemotherapy is highly effective in treating...
Read More
In a nutshell This study evaluated the outcomes of removing radiotherapy from treatment for patients with early-stage Hodgkin lymphoma (HL). This study concluded that radiotherapy improved survival without disease progression for patients while omitting it did not affect overall survival. Some background Chemotherapy followed by radiotherapy (RT)...
Read More
In a nutshell This study evaluated the outcomes of a stem cell transplant after nivolumab (Opdivo) therapy in patients with classical Hodgkin’s lymphoma (cHL) that came back or stopped responding to treatment. This study concluded that nivolumab followed by stem cell transplant is safe and effective for these patients. Some background...
Read More
In a nutshell This article reviewed treatments and outcomes for children and adolescents with Hodgkin’s lymphoma (HL). The authors found that chemotherapy alone was a common treatment and that outcomes have improved for these young patients. Some background Hodgkin’s lymphoma (HL) is a cancer of the white blood cells. It can affect both...
Read MoreIn a nutshell This study compared the outcomes of patients with lymphoma who had an allogeneic stem cell transplant with different sources of stem cells. This study found that stem cells from a matching donor had better outcomes compared to those from unrelated cord blood. Some background Allogeneic stem cell transplantation is one type of stem...
Read More
In a nutshell This study looked at the outcomes of autologous stem cell transplantation (ASCT) to treat recurrent classical Hodgkin’s lymphoma (cHL). This study concluded that ASCT is effective, with patients who responded after the transplant having the best outcomes. Some background cHL is usually treated with chemotherapy and...
Read More
